XML 24 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 131,329 $ 80,428
Marketable securities 510,094 282,046
Interest receivable 1,035 682
Accounts receivable 5,224 36,909
Prepaid expenses and other current assets 11,986 5,408
Total current assets 659,668 405,473
Marketable securities, non-current 50,530 21,832
Property and equipment, net 41,324 29,926
Intangible assets 58,128 53,156
Goodwill 42,798 39,273
Operating lease right-of-use assets 71,045 77,289
Other non-current assets 13,557 9,067
Restricted cash 1,500 1,500
Total assets 938,550 637,516
Current liabilities:    
Accounts payable 12,553 6,671
Other accrued liabilities 18,612 10,885
Accrued compensation and employee benefits 20,738 13,605
Deferred revenues 91,644 38,711
Total current liabilities 143,547 69,872
Deferred revenues, non-current 245,045 81,432
Long-term portion of lease liabilities 38,396 41,192
Deferred income tax 7,185 6,570
Other non-current liabilities 7,011 5,711
Total liabilities 441,184 204,777
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.01 par value, 5,000,000 shares authorized, and no shares issued or outstanding 0 0
Common stock, $0.01 par value; 320,000,000 shares authorized, 142,063,203 and 115,972,708 shares issued and outstanding at December 31, 2020 and 2019, respectively 1,421 1,160
Additional paid-in capital 1,269,375 1,090,828
Accumulated deficit (777,981) (656,985)
Accumulated other comprehensive income (loss) 5,419 (2,449)
Total Sangamo Therapeutics, Inc. stockholders’ equity 498,234 432,554
Non-controlling interest (868) 185
Total stockholders’ equity 497,366 432,739
Total liabilities and stockholders’ equity $ 938,550 $ 637,516